Efficacy of acupuncture for endometriosis-associated pain: a multicenter randomized single-blind placebo-controlled trial

Objective: To evaluate the efficacy and safety of acupuncture in the treatment of endometriosis-associated pain.Design: A multicenter, randomized, single-blind, placebo-controlled trial.Institutions: Four tertiary hospitals in Jiangxi and Hainan Provinces. Subjects: Women with endometriosis-associated pain aged between 20 and 40 years.Intervention: Subjects were assigned randomly to receive either acupuncture or sham acupuncture treatment for 12 weeks, starting one week before each expected menstruation and administered as a 30-minute session once per day, 3 times a week. During the menstruation period, acupuncture was administered daily when pelvic pain associated with endometriosis occurred. After acupuncture or sham acupuncture treatment, the subjects were followed for another 12 weeks.Main Outcome Measures: Changes in maximum pain as assessed with the visual analog scale (VAS) for various pelvic pain, duration of dysmenorrhea, and scores on the Multidimensional Pain Inventory, Beck Depression Inventory, Profile of Mood States, and Endo-metriosis Health Profile from baseline to week 12 and week 24. Results: A total of 106 women were assigned randomly to the acupuncture and sham groups. In the acupuncture group, the reduction in the dysmenorrhea VAS score was significantly greater after treatment, but not at the end of the trial, compared to the sham group. The duration of pain was significantly shorter in the acupuncture group. All test scores were improved to a significantly greater extent in the acupuncture group than in the sham group at week 12 but not at week 24. Changes in nonmenstrual pelvic pain and dyspareunia VAS scores were not different between the groups. No severe adverse events or differences in adverse events were recorded.Conclusion: Acupuncture is an effective and safe method of relieving dysmenorrhea, shortening the pain duration, and improving wellbeing and quality of life in women with endometriosis-associated pain, although its efficacy fades after treatment is discontinued.Clinical Trial Registration number: NCT03125304. (Fertil Sterile 2023;119:815-23. (c) 2023 by American Society for Reproductive Medicine.)